{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T13:24:07Z","timestamp":1781961847759,"version":"3.54.5"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T00:00:00Z","timestamp":1434585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0129648","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T18:02:57Z","timestamp":1434650577000},"page":"e0129648","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy"],"prefix":"10.1371","volume":"10","author":[{"given":"Wiltrud","family":"Haa\u00df","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Karsten","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Fabarius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Seifarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Schweizerische Arbeitsgemeinschaft f\u00fcr Klinische Krebsforschung (SAKK) and the German CML Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,6,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"CL Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"B Calabretta","year":"2004","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","article-title":"Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib","volume":"119","author":"A Kumari","year":"2012","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"D Perrotti","year":"2010","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML","volume":"100","author":"ME O'Dwyer","year":"2002","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"E Bolton-Gillespie","year":"2013","journal-title":"Blood"},{"key":"ref8","first-page":"121","article-title":"Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R","volume":"31","author":"J Rosenhahn","year":"2007","journal-title":"Int J Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/gcc.20801","article-title":"Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML","volume":"49","author":"S Schnittger","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Non-random karyotypic evolution in chronic myeloid leukemia","volume":"18","author":"F Mitelman","year":"1976","journal-title":"Int J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2004.03.012","article-title":"Clonal evolution in chronic myelogenous leukemia","volume":"18","author":"J Cortes","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"A Fabarius","year":"2011","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"ME O'Dwyer","year":"2004","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"C Schoch","year":"2003","journal-title":"Leukemia"},{"issue":"Suppl","key":"ref15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/mdp143","article-title":"Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"M Baccarani","year":"2009","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nature08136","article-title":"A mechanism linking extra centrosomes to chromosomal instability","volume":"460","author":"NJ Ganem","year":"2009","journal-title":"Nature"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/sj.leu.2403779","article-title":"Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability","volume":"19","author":"M Giehl","year":"2005","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1073\/pnas.032479999","article-title":"Centrosome amplification drives chromosomal instability in breast tumor development","volume":"99","author":"WL Lingle","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.7150\/ijbs.7.1122","article-title":"A clinical overview of centrosome amplification in human cancers","volume":"7","author":"JY Chan","year":"2011","journal-title":"Int J Biol Sci"},{"key":"ref20","first-page":"1398","article-title":"Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas","volume":"63","author":"GA Pihan","year":"2003","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"8995","DOI":"10.1073\/pnas.0700631104","article-title":"Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations","volume":"104","author":"C Gao","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/embor.2012.55","article-title":"Losing balance: the origin and impact of aneuploidy in cancer","volume":"13","author":"AJ Holland","year":"2012","journal-title":"EMBO Rep"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.leu.2404834","article-title":"Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells","volume":"21","author":"M Giehl","year":"2007","journal-title":"Leukemia"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1365-2141.2009.07772.x","article-title":"Abnormal centrosome-centriole cycle in chronic myeloid leukaemia?","volume":"146","author":"H Patel","year":"2009","journal-title":"Br J Haematol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cancergencyto.2004.06.011","article-title":"Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression","volume":"157","author":"U Bacher","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2403861","article-title":"Induction of centrosome and chromosome aberrations by imatinib <italic>in vitro<\/italic>","volume":"19","author":"A Fabarius","year":"2005","journal-title":"Leukemia"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3324\/haematol.12793","article-title":"Centrosome aberrations and G1 phase arrest after <italic>in vitro<\/italic> and <italic>in vivo<\/italic> treatment with the SRC\/ABL inhibitor dasatinib","volume":"93","author":"A Fabarius","year":"2008","journal-title":"Haematologica"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/sj.leu.2403399","article-title":"Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia","volume":"18","author":"C Terre","year":"2004","journal-title":"Leukemia"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2010.01459.x","article-title":"Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors","volume":"85","author":"M Giehl","year":"2010","journal-title":"Eur J Haematol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.tcb.2007.03.003","article-title":"Centrosome duplication: of rules and licenses","volume":"17","author":"EA Nigg","year":"2007","journal-title":"Trends Cell Biol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/ncb2280","article-title":"Cleavage of cohesin rings coordinates the separation of centrioles and chromatids","volume":"13","author":"L Schockel","year":"2011","journal-title":"Nat Cell Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.4161\/cc.9.9.11792","article-title":"Cohesin: it&apos;s not just for chromosomes anymore","volume":"9","author":"LA Simmons-Kovacs","year":"2010","journal-title":"Cell Cycle"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1083\/jcb.200906019","article-title":"Centrosomal Aki1 and cohesin function in separase-regulated centriole disengagement","volume":"187","author":"A Nakamura","year":"2009","journal-title":"J Cell Biol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.devcel.2009.07.015","article-title":"Polo kinase and separase regulate the mitotic licensing of centriole duplication in human cells","volume":"17","author":"MF Tsou","year":"2009","journal-title":"Dev Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1158\/1078-0432.CCR-08-2454","article-title":"Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers","volume":"15","author":"R Meyer","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2013.493","article-title":"MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ER\u03b1)-positive mammary adenocarcinomas","volume":"33","author":"M Mukherjee","year":"2014","journal-title":"Oncogene"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11060-014-1458-6","article-title":"Overexpression and constitutive nuclear localization of cohesin protease Separase protein correlates with high incidence of relapse and reduced overall survival in glioblastoma multiforme","volume":"119","author":"M Mukherjee","year":"2014","journal-title":"J Neurooncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1073\/pnas.0730733100","article-title":"Processing, localization, and requirement of human separase for normal anaphase progression","volume":"100","author":"A Chestukhin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/embj.201488098","article-title":"PP2A delays APC\/C-dependent degradation of separase-associated but not free securin","volume":"33","author":"S Hellmuth","year":"2014","journal-title":"EMBO J"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1242\/jcs.03083","article-title":"Cyclin-B1-mediated inhibition of excess separase is required for timely chromosome disjunction","volume":"119","author":"AJ Holland","year":"2006","journal-title":"J Cell Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/S0960-9822(02)01073-4","article-title":"Regulation of human separase by securin binding and autocleavage","volume":"12","author":"I Waizenegger","year":"2002","journal-title":"Curr Biol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e42863","DOI":"10.1371\/journal.pone.0042863","article-title":"The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib","volume":"7","author":"W Haass","year":"2012","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1289\/ehp.01109801","article-title":"The immortalized UROtsa cell line as a potential cell culture model of human urothelium","volume":"109","author":"MR Rossi","year":"2001","journal-title":"Environ Health Perspect"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"KJ Livak","year":"2001","journal-title":"Methods"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ab.2009.05.046","article-title":"Development and validation of a fluorogenic assay to measure separase enzyme activity","volume":"392","author":"D Basu","year":"2009","journal-title":"Anal Biochem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"DJ Barnes","year":"2005","journal-title":"Cancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"M Deininger","year":"2005","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"P Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"R Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S0959-8049(00)00128-3","article-title":"The possible influences of B2A2 and B3A2 BCR\/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia","volume":"36","author":"RA Perego","year":"2000","journal-title":"Eur J Cancer"},{"key":"ref51","first-page":"148","article-title":"Cancer karyotypes: survival of the fittest","volume":"7","author":"JM Nicholson","year":"2013","journal-title":"Front Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"E Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"D Verma","year":"2010","journal-title":"Cancer"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"B Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/1087057114520972","article-title":"Identification and Characterization of Separase Inhibitors (Sepins) for Cancer Therapy","volume":"19","author":"N Zhang","year":"2014","journal-title":"J Biomol Screen"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0129648","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:43:30Z","timestamp":1748457810000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0129648"}},"subtitle":[],"editor":[{"given":"Peyman","family":"Bj\u00f6rklund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,18]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0129648","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,18]]}}}